N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
Overactive Bladder With Urge Urinary Incontinence
Primary: Change From Baseline at Week 12 in Average Daily Number of Urgency Episodes — -1.13; -2.43; -3.37 Urgency episodes per day — p==0.1722
N/A N=18 Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?
Overactive Bladder
Primary: Number of Subjects With Evidence of Bacteria in Urine Sample by Microbiologic Evaluation — 8; 1 participants
N/A N=20 Hypnotherapy for Treatment of Overactive Bladder
Overactive Bladder
Primary: Change in Overactive Bladder Symptoms (Based on OABqSF) — -19; -33.4 units on a scale — p=.07
Phase 1 N=20 A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
Overactive Bladder
Primary: Change From Baseline in Maximum Cystometric Capacity at 4 Hours Post Dose 7 on Tolterodine 4 mg and Placebo — 1.15; 0.94 Percentage change — p=0.008
N/A N=22 Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity
Overactive Detrusor
Primary: Mean Peak Detrusor Pressures — 58; 31 cm H2O
Phase 4 N=23 Treatment of Incontinence Without Memory Problems
Urge Incontinence · Urinary Incontinence, Urge
Primary: The Number of Participants Who Completed and Discontinued the Study — 11; 10; 1; 1 Participants — p=0.949
Phase 2 N=76 Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
Detrusor Underactivity · Overactive Bladder
Primary: Changes in the Mean BCI for Male From Baseline to Week 12 — 64.604; 61.339; 75.156; 60.513 Score on a scale — p=<0.001
Phase 2 N=106 Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
Overactive Bladder
Primary: Change in Mean Number of Nocturnal Voids From Baseline — -1.63; -1.29 Voids — p=0.112
Phase 3 N=143 Behavioral Treatment of Overactive Bladder in Men
Overactive Bladder
Primary: 24-hour Voiding Frequency — 9.1; 9.5 voids per 24-hour day — p=.001
Phase 3 N=249 Anticholinergic vs. Botox Comparison Study
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin
Phase 3 N=947 Fesoterodine "add-on" Male Overactive Bladder Study
Overactive Bladder Syndrome
Primary: Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 12 — -3.2; -2.9 number of episodes — p=0.1959
Phase 4 N=990 A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.
Urinary Bladder, Overactive
Primary: Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours — 3.93; 1.60 episodes per 24 hours — p=<0.0001
N/A N=20 Amplifying Sensation in Underactive Bladder
Urinary Bladder, Underactive
Primary: Voiding Efficiency — 32; 53; 43; 46 voided percentage — p=1
Phase 2 N=47 Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Detrusor Muscle Hyperactivity
Primary: Daily Incontinence Episode Frequency (IEF) — 4.21; 3.33; 3.23; 4.40 episodes per day — p=0.11
N/A N=58 Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms
Overactive Bladder
Primary: Evaluate Subjective Patient Change in Irritative Urinary Symptoms as Measured by the Overactive Bladder Questionnaire (OAB-q) Symptom Bother Score — 65.4; 61.6; 46.7…
N/A N=84 Treatment for Acute Postoperative Voiding Dysfunction
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
Phase 3 N=35 Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder
Overactive Bladder · Urinary Incontinence
Primary: Response to Urinary Incontinence as a Composite Measure of Efficacy of add-on Mirabegron — 12; 23 Participants
Phase 4 N=23 Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
Overactive Bladder in Parkinson's Disease
Primary: Number of Micturations Per 24 Hour Period — 8.78; 9.19; 8.00; 8.94 Number of micturations per 24 hours — p=0.53
Phase 4 N=100 Overactive Bladder Innovative Therapy Trial (OrBIT)
Overactive Bladder
Primary: Frequency of Voids at 12 Weeks — -2.4; -2.5 Voids/day
Phase 3 N=386 Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)
Urinary Incontinence, Urge
Primary: Number of Urge Urinary Incontinence (UUI) Episodes — -3.25; -3.89 UUI episodes
Phase 4 N=20 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
Parkinson's Disease · Neurogenic Bladder · Urinary Incontinence
Primary: Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment. — 0 participants
Phase 2 N=9 Botulin-A Toxin Instillations and Overactive Bladder
Overactive Bladder · Detrusor Instability · Detrusor Hyperreflexia
Primary: Median Number of Incontinent Episodes During 24 Hours — 4; 2; 4 number of incontinent episodes — p=0.004
Phase 1 N=51 Study of V117957 in Overactive Bladder Syndrome
Overactive Bladder Syndrome
Primary: Change From Baseline in Micturition Episode Components (Micturition, Incontinence, and Urgency) Per 24 Hours. — -0.8; -0.8; -0.2; -0.4 Episodes per 24 hours
Phase 4 N=254 OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Overactive Bladder
Primary: Percentage of Participants Who Achieve a 100% Reduction in Urinary Incontinence Episodes — 32.0; 7.2 percentage of participants
Phase 3 N=248 Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
Urinary Bladder, Overactive
Primary: Treatment Phase 1 (Treatment Cycle 1): Change From Baseline in the Daily Average Number of Urinary Incontinence Episodes at Week 12 After the First Treatment — -1.25…
Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
Phase 2 N=550 SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
Overactive Bladder Syndrome (OABS)
Primary: Change From Baseline to Week 8 in the Number of Voids/24 Hours — -1.06; -1.44; -1.78; -2.41 voids/24 hrs.
Phase 1 N=23 Autologous Muscle Derived Cells for Underactive Bladder
Urinary Retention · Urinary Incontinence
Primary: Number of Participants With Study-related Adverse Events at 6 Months — 2; 1; 1; 1 participants
Phase 4 N=46 Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
Benign Prostatic Hyperplasia (BPH)
Primary: Post-void Residual (PVR) Volume — 101.7; 75.8 mL